Follow us on
Welcome Guest! You are here: Home » Health
Siberian scientists develop anticancer drug from human breast milk
Wednesday March 11, 2015 10:45 PM, IINA

Clinical tests are underway in Russia on medicines to combat cancer and tick borne encephalitis, following studies on lactaptin – human breast milk.

The drug, unmatched worldwide, was created by scientists at the Siberian Branch of Russian Academy of Sciences.

A special center for conducting the clinical trials on the medication, which expected to cure cancer and tick borne diseases, was established in the city of Novosibirsk.

In statements carried by Radio Russia and published by Qatar News Agency (QNA) on Wednesday, Valentin Vlasovs, director of the Siberian Institute of Chemical Biology and Fundamental Medicine, said: "It is a new product name "Laktoptin" made from mother's milk, which is necessary to routinely maintain the count of cells and their functions in multicellular objects, as well as to expel the infected and cancer cells".

He added that the treatment for diseases caused by tick bites, is a special antibodies product, whose effectiveness is greater than "Immunoglobulin", noting that its clinical test is likely to be completed before that of the anti-cancer medication.



Share this page
 Comments
Note: By posting your comments here you agree to the terms and conditions of www.ummid.com
comments powered by Disqus
Advertisement
| Quick links
About ummid.com
Contact us
Feedback
Subscribe to: RSS » Facebook » Twitter » Newsletter
Ummid.com: Disclaimer | Terms of Use | Advertise with us | Link Exchange
Ummid.com is part of the Awaz Multimedia & Publications providing World News, News Analysis and Feature Articles on Education, Health. Politics, Technology, Sports, Entertainment, Industry etc. The articles or the views displayed on this website are for public information and in no way describe the editorial views. The users are entitled to use this site subject to the terms and conditions mentioned.
© 2012 Awaz Multimedia & Publications. All rights reserved.